The CRISPR‐Trap strategy allows specific action on the BCR/ABL oncogene, providing promising results in the treatment of CML patients, especially those who do not have a satisfactory response to tyrosine kinase inhibitors. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.